|
Patent landscape, scope, and claims: |
United States Patent 8,410,088 (US8410088): Scope, Claim Coverage, and US Patent Landscape for Formula (Ig)/Compounds and Pharmaceutical Compositions
What does US 8,410,088 protect: scope of claims 1-25 and practical chemical coverage?
US 8,410,088 is a broad Markush-structure patent that claims a large genus of small-molecule compounds defined by a multi-variable scaffold (Formula (Ig)), plus dependent subsets, plus pharmaceutical compositions and salts. The operative infringement hook is the presence of the claimed structural relationship among the variables R2, R4, R6, R7, R8 and their linkers/substituents as defined in Formula (Ig), including optional ring closures and heteroatom-containing groups.
Independent claim structure: what is actually being claimed?
Claim 1 claims:
- A compound of Formula (Ig) (or a pharmaceutically acceptable salt).
- Key variable-driven constraints:
- R2, R4, R12: each is independently C1-6 alkyl.
- R6: C6-C10 aryl or 5- or 6-membered heteroaryl, optionally substituted with fragments -Q2-T2.
- R7: -Q4-T4, where Q4 is bond or linker/alkenyl linker and T4 is a variable group (H/halo/cyano/substituted amines/heterocycles/aryl/aryl-like and sulfonamides and oxo).
- R8: H/halo/hydroxyl/COOH/cyano or RS6/ORS6/COORS6, with RS6 limited to specific alkyl/alkenyl/alkynyl/cycloalkyl/heterocycloalkyl/amino/alkylamino classes and optional substitutions.
- Additional branch: R7 and R8 can cyclize with the same N atom to form a 4-11 member heterocycloalkyl ring (0 to 2 additional heteroatoms), optionally substituted via -Q6-T6.
- The claim permits substantial combinatorial substitution:
- Substitution via Q2-T2, Q3-T3, Q4-T4, Q5-T5, and Q6-T6
- Multiple families of functional groups: halo, cyano, hydroxyl, alkoxy, amino/alkylamino, sulfonamide motifs (S(O)2R; S(O)2NRaRb), carboxylates and acyls (C(O)Ra, C(O)ORa, C(O)NRaRb), and “oxo”.
Dependent claims: where the coverage narrows
Claims 2-8 and 9-25 carve out narrower subgenera that are still likely to be commercially relevant.
- Claim 2 narrows substituent universe for R6:
- Focuses R6 as aryl/heteroaryl with fewer specific options for T2 (e.g., includes H/halo/cyano/ORa/NRaRb/(NRaRbRc)+A−/S(O)2NRaRb; limits RS2/RS3 to alkyl or a cyclized heterocycle with a constrained ring size).
- Claim 3 pins to Formula (II) within Formula (Ig):
- Q2 = bond or methyl; T2 restricted (H/halo/ORa/NRaRb/(NRaRbRc)+A−/S(O)2NRaRb).
- R7 limited to piperidinyl, tetrahydropyran, cyclopentyl, cyclohexyl (optionally substituted with one -Q5-T5).
- R8 = ethyl.
- Claim 4 defines Formula (IIa) subset:
- Similar overall Markush framework but with constraints including provided that R7 is not H, and variable substitution rules for Q3/T3, Q4/T4, Q5/T5, and R8/RS6.
- Claims 5-8 add further constraints and explicit ring/sidechain selections:
- Claim 5: ring formed by Ra/Rb at N is a 4-7 member heterocycle (0 or 1 additional heteroatom), enumerating heterocycle types (azetidinyl through morpholinyl).
- Claim 6: R7 limited to cycloalkyl or 4-7 heterocycloalkyl, each optionally substituted via -Q5-T5.
- Claim 7: enumerates R7 as piperidinyl/tetrahydropyran/tetrahydro-2H-thiopyranyl/cyclopentyl/cyclohexyl/pyrrolidinyl/cycloheptyl.
- Claim 8: R8 limited to H or C1-6 alkyl (optionally substituted set includes halo/hydroxyl/COOH/carbamates/carboxylates/cyano/alkoxyl/amino/alkylamino).
- Claims 9: “selected from and pharmaceutically acceptable salts thereof” for the compounds of claim 1 (this is a dependent “selection claim” that typically supports narrower lists for enforcement, but it does not independently expand beyond the Markush universe already present).
- Claims 10, 15, 13, 14, 16-25 are pharmaceutical composition claims covering the claimed compound or salt with a pharmaceutically acceptable carrier.
Claim 11 and claim 12: what are they, structurally?
The excerpt you provided lists “A compound, which is …” and “A pharmaceutically acceptable salt of …” but the actual definitions after those phrases are not included. Because the chemical definitions are missing, a complete scope construction for claims 11 and 12 cannot be derived from your text.
How broad is the Formula (Ig) Markush genus: which substituent dimensions drive the largest coverage?
The breadth comes from:
-
R6 aryl/heteroaryl substitution density
- R6 can be broadly selected (C6-C10 aryl or 5/6 heteroaryl).
- Optional substitution via repeated Q2-T2 and then substituent families T2 that can themselves be substituted via Q3-T3.
-
R7 substituent/heterocycle flexibility
- R7 is defined through Q4-T4, where Q4 can be bond, alkyl linker, or alkenyl linker, and T4 can be multiple heterocycles/alkyl aryl-like groups or amide/sulfonamide/amine forms, plus oxo.
- R7 can alternatively cyclize with R8 on the N atom into a heterocycle. That cyclization path can capture additional structural designs that might not be “direct substituent swaps.”
-
R8 functional handle
- R8 can be small functional groups (H/halo/hydroxyl/COOH/cyano) or selected RS6 substituents (alkyl/alkenyl/alkynyl/cycloalkyl/heterocycloalkyl or amines/alkylamino), with optional substitution options.
Practical coverage summary: what designs likely fall within the claim?
A compound is likely within claim 1 if it matches:
- A scaffold where two positions (R2, R4, R12) are small alkyl (C1-6).
- An aryl/heteroaryl group at R6 that bears substituent patterns consistent with Q2-T2, where T2 is limited to specific functional groups/heterocycles and may be further substituted via Q3-T3.
- A R7 substituent that is either:
- a constrained functional group / heterocycle / ring system described by T4 and -Q4 linker, or
- forms the alternative cyclized heterocycloalkyl with R8 on the same N.
- A R8 substituent that is small or limited RS6/ORS6/COORS6 families with defined optional substitution classes.
How do dependent claims (2-8) narrow the genus: what subfamilies are enumerated?
Claim 2 narrows R6 substitution and side chain heterocycle possibilities.
Claims 3 and 4 are “formula-labeled” subsets that tend to correspond to specific lead series in the original disclosure.
Claims 5-8 enumerate ring sizes and specific heterocycles for the N-adjacent sidechain variables and list allowed R7 ring systems, which makes those claims more directly searchable in freedom-to-operate screen workflows.
Enumerated heterocycles in claim 5
The ring formed by Ra/Rb with the N atom (4 to 7 member heterocycloalkyl, 0 or 1 additional heteroatom) includes:
- azetidinyl
- pyrrolidinyl
- imidazolidinyl
- pyrazolidinyl
- oxazolidinyl
- isoxazolidinyl
- triazolidinyl
- piperidinyl
- 1,2,3,6-tetrahydropyridinyl
- piperazinyl
- morpholinyl
R7 enumerations in claim 7
- piperidinyl
- tetrahydropyran
- tetrahydro-2H-thiopyranyl
- cyclopentyl
- cyclohexyl
- pyrrolidinyl
- cycloheptyl
These explicit enumerations matter for enforcement and for generics: products that deviate only by swapping within these lists are less likely to avoid infringement compared with products that switch to disallowed heterocycles (e.g., 8-member azepane-type structures if excluded).
What is the likely “infringement map”: which claim elements are most difficult to design around?
From the claim text alone, the design-around risks cluster on three elements:
-
The R2/R4/R12 requirement
- Each must be C1-6 alkyl. This is a relatively tight constraint if a competitor uses aryl/heteroaryl or polar substituted substituents at those positions.
-
The R6 aromatic/heteroaryl substitution architecture
- R6 is defined with broad selection, but the permitted functional group types for T2 and the downstream substitution options for T3 are constrained. Avoidance would require stepping outside the functional group set or the allowed linker/substituent definitions.
-
R7/R8 relationship
- The claim includes both:
- specific R7 substituent architectures, and
- an alternate cyclization where R7 and R8 form a ring with the N atom.
- That dual pathway increases coverage against competitors that might otherwise try to avoid a specific open-chain R7 arrangement by instead cyclizing.
What formulations are protected: scope of composition claims 10, 13-15, 16-25?
The composition claims are straightforward:
- Pharmaceutical composition comprising:
- the compound of claim 1 (or salt), or
- the compound of claim 4/3 (Formula (IIa)/(II)), or
- the compound/salt of dependent claims,
- plus a pharmaceutically acceptable carrier.
Practical implications
- These composition claims generally cover:
- any dosage form where the claimed compound/salt is present, unless the competitor can argue that their product uses a materially different active species (different salt form not encompassed) or a non-covered analog.
- Composition claims also typically support enforcement for combination products only if the active ingredient matches the claimed compounds/salts.
Patent landscape in the US: what claims suggest about the broader patent estate?
With only the claim text, the most defensible landscape inference is type-of-estate, not specific family members:
- This is a small-molecule genus/Markush patent, typically paired with:
- earlier priority chemistry patents (lead series),
- later refinement patents (specific exemplars, polymorphs, salts, or intermediates),
- and at least one or more formulation/device patents depending on the product.
However, without the publication number, assignee, family members, prosecution history, or listed citations in the record, a complete US landscape map (other US patents in the family, continuations, divisionals, or expiration dates) cannot be produced from the information provided.
When does US 8,410,088 lose exclusivity: what can be concluded from the claim set alone?
No exclusivity timeline can be calculated from the claim excerpt. Patent term and any pediatric extension, PTA, or FDA-related exclusivity require record facts (filing dates, grant date, and regulatory linkage). No such facts are included in the provided text, so an exclusivity/expiration timetable cannot be stated.
How strong is the patent estate for enforcement: claim construction pressure points
Even without litigation data, the claim structure indicates the principal enforcement strengths:
- The independent claim is broad at the genus level through extensive Markush variables.
- Dependent claims add specific enumerated subgenera, supporting multiple fallback positions.
Primary pressure points for a challenger:
- Invalidity arguments would likely target:
- whether the breadth is supported by the specification (enablement and written description),
- and whether the claimed genus is too broad relative to disclosed examples.
- Non-infringement would likely focus on:
- R2/R4/R12 substituent identity,
- and whether competitor structures use substituents outside the defined sets for T2/T3/T4/T5/T6, or alter linker chemistry beyond the allowed Q definitions,
- plus whether a competitor’s cyclization/heterocycle formation at the N node changes the relationship outside the claimed ring sizes and heteroatom counts.
Generic entry risks: what kind of competitor design would likely avoid claim 1?
A generic or new entrant would need to move outside at least one material claim constraint:
- Replace one of R2/R4/R12 with a substituent not within C1-6 alkyl.
- Use an R6 aromatic/heteroaryl system where the substituent pattern does not map to allowed -Q2-T2 / Q3-T3 constructions.
- Redesign R7/R8 such that:
- the open-chain R7 substituent falls outside allowed Q4-T4 options, or
- the cyclized R7/R8 heterocycloalkyl ring has a ring size or heteroatom count outside 4-11 with 0-2 additional heteroatoms, or is substituted with groups not covered by -Q6-T6.
Key Takeaways
- US 8,410,088 Claim 1 is a broad Markush genus claim over Formula (Ig) compounds with tight constraints on key positions (notably R2/R4/R12 = C1-6 alkyl) and detailed allowed substituent families on R6, R7, and R8.
- Dependent claims 3-8 identify narrower, likely commercially meaningful subsets by constraining to Formula (II)/(IIa) and enumerating specific heterocycles for N-adjacent and R7 substituents.
- Composition claims cover pharmaceutical compositions using the claimed compound or salt with standard “pharmaceutically acceptable carrier” language.
- A credible design-around requires changing at least one material structural rule (R2/R4/R12 substituent identity, R6 substituent functional-group sets, or R7/R8 cyclization/ring-size/heteroatom/substitution restrictions).
- A complete US patent landscape (family members, litigation status, expiration/exclusivity dates, Orange Book linkage, and Paragraph IV risk) cannot be derived from the claim text alone.
FAQs
1) Does US 8,410,088 require R2/R4/R12 to be exactly C1-6 alkyl?
Yes. Claim 1 states R2, R4, and R12 are each independently C1-6 alkyl.
2) Can the patent cover both open-chain R7/R8 substituents and ring-closed R7/R8 forms?
Yes. Claim 1 includes both the defined R7 and R8 substituent options and an alternative where R7 and R8 cyclize with the N atom to form a heterocycloalkyl ring (with size and heteroatom limits).
3) Are sulfonamide and amide functional groups within scope?
Yes. Claim 1 includes T2/T4/T5/T6 options containing patterns such as —S(O)2Ra, —S(O)2NRaRb, —C(O)Ra, —C(O)ORa, and —C(O)NRaRb, among other variants.
4) Do the composition claims limit dosage form or route of administration?
The composition claims in the excerpt use generic “pharmaceutically acceptable carrier” language, not dosage-form-specific limitations.
5) Which dependent claims most directly enumerate commercially relevant rings?
Claims 5 and 7 enumerate specific heterocycloalkyl ring types (claim 5 for the Ra/Rb ring with N; claim 7 for R7 options).
References (APA)
- U.S. Patent No. 8,410,088 (claims as provided in user prompt).
More… ↓
⤷ Start Trial
|
